Literature DB >> 11259172

Identification and characterization of a novel mutation c.1090G>T (G325W) and nine common mutant alleles leading to Gaucher disease in Spanish patients.

M A Torralba1, J I Pérez-Calvo, G M Pastores, A Cenarro, P Giraldo, M Pocoví.   

Abstract

BACKGROUND: Gaucher disease is an autosomal recessive disorder resulting from mutations in the glucocerebrosidase gene (GBA). The lack of full genotype/phenotype correlation complicates counseling regarding clinical outcome and treatment recommendations. SUBJECTS AND METHODS: Several mutations in the human beta-glucosidase gene associated with Gaucher disease in 16 Spanish families were identified utilizing a combination of methods: enzymatic restriction, PCR-SSCP, and sequence analyses. Expression studies were performed following the introduction of the mutagenized human acid beta-glucosidase cDNA into COS-1 cells, and the residual enzyme activities of the mutant protein were measured and compared with the normal cDNA.
RESULTS: The identified mutations and corresponding residual enzyme activities of the expressed protein are as follows: c.517A>C (T134P), 1%; c.721G>A (G202R), 17%; c.1090G>T (G325W), 13.9%; c.1093G>A (E326K), 26%; c.1208G>A (S364N), 4.1%; c.1226A>G (N370S), 17,8%; c.1246G>A (G377S), 17.6%; c.1289C>T (P391L), 8.5%; c.1448T>C (L444P), 3%; and c.1504C>T (R463C), 24.5%.
CONCLUSIONS: Site-directed mutagenesis and expression in COS-1 cells are useful methods to increase our understanding of causality in Gaucher disease and the correlation between disease severity, gene defects, and residual enzyme activity. Our study demonstrates the functional consequences of the identified human beta-glucosidase mutations (T134P, S364N, G377S, P391L, and G325W) and provide evidence for the molecular and biochemical basis of Gaucher disease, among patients of Spanish ancestry. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11259172     DOI: 10.1006/bcmd.2001.0410

Source DB:  PubMed          Journal:  Blood Cells Mol Dis        ISSN: 1079-9796            Impact factor:   3.039


  4 in total

Review 1.  Type 2 Gaucher disease: phenotypic variation and genotypic heterogeneity.

Authors:  N Gupta; I M Oppenheim; E F Kauvar; N Tayebi; E Sidransky
Journal:  Blood Cells Mol Dis       Date:  2010-09-28       Impact factor: 3.039

Review 2.  GBA Variants and Parkinson Disease: Mechanisms and Treatments.

Authors:  Laura Smith; Anthony H V Schapira
Journal:  Cells       Date:  2022-04-08       Impact factor: 7.666

3.  Nine-year experience in Gaucher disease diagnosis at the Spanish reference center Fundación Jiménez Díaz.

Authors:  N V Ortiz-Cabrera; J Gallego-Merlo; C Vélez-Monsalve; R de Nicolas; S Fontao Mas; C Ayuso; M J Trujillo-Tiebas
Journal:  Mol Genet Metab Rep       Date:  2016-11-13

4.  Association of GBA Mutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease.

Authors:  Marie Y Davis; Catherine O Johnson; James B Leverenz; Daniel Weintraub; John Q Trojanowski; Alice Chen-Plotkin; Vivianna M Van Deerlin; Joseph F Quinn; Kathryn A Chung; Amie L Peterson-Hiller; Liana S Rosenthal; Ted M Dawson; Marilyn S Albert; Jennifer G Goldman; Glenn T Stebbins; Bryan Bernard; Zbigniew K Wszolek; Owen A Ross; Dennis W Dickson; David Eidelberg; Paul J Mattis; Martin Niethammer; Dora Yearout; Shu-Ching Hu; Brenna A Cholerton; Megan Smith; Ignacio F Mata; Thomas J Montine; Karen L Edwards; Cyrus P Zabetian
Journal:  JAMA Neurol       Date:  2016-10-01       Impact factor: 18.302

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.